Here's the latest from the AASLD Conference:
Official Conference Coverage of the 2015 Annual Meeting of the American Association for the Study of Liver Diseases
David R. Nelson, MD
Norah Terrault, MD, MPH
Review the most important studies from The Liver Meeting 2015. Selected by experts David R. Nelson, MD, and Norah Terrault, MD, MPH, each Capsule Summary presents the key data and figures from a vital study presented at the meeting. The following Capsule Summaries are now available:
In partnership with
ASTRAL-1: 99% SVR Rate With 12 Weeks of Sofosbuvir/Velpatasvir in Treatment-Naive or Treatment-Experienced Patients With Genotype 1, 2, 4, 5, or 6 HCV Infection
High SVR rates maintained across patient subgroups, including cirrhotic and treatment-experienced patients; adverse event rates similar to placebo.
HCV-TARGET: 8-24 Weeks of Ledipasvir/Sofosbuvir Highly Effective Against Genotype 1 HCV in Real-World Settings
Analysis finds 8-week regimen is underused, despite being highly effective in qualifying patients.
High SVR Rates With 12-24 Weeks of Daclatasvir Plus Sofosbuvir With or Without RBV in Patients With Genotype 3 HCV and Advanced Liver Disease
Use of shorter 12-week treatment regimen highly effective in patients with F3 disease.
High SVR12 Rates With Ravidasvir Plus Sofosbuvir With or Without Ribavirin in Cirrhotic and Noncirrhotic Patients With Genotype 4 HCV Infection
No relapse in noncirrhotic patients regardless of inclusion of ribavirin; no relapse in cirrhotic patients with 16 weeks of treatment including ribavirin.
These Capsule Summaries are part of CCO's Official Conference Coverage: Clinical Impact of New Data From AASLD 2015. For more coverage, including forthcoming Capsule Summaries, please visit clinicaloptions.com/2015AASLD.
Coming soon: CME-certified Expert Analysis: leading experts discuss the clinical implications of new data from the meeting in San Francisco
If you want to read more, go to:
You have to create an account but it's easy and they will send you updates via email